Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Guardant Health, Inc. logo

Guardant Health, Inc. (GH) Stock Ticker

NASDAQ: GH · Healthcare · Medical - Diagnostics & Research
$177.83+0.45%
USD · as of 2026-09-28 · market cap $23.8B
Open GH in TickrDownload for iPhone

GH right now

Growing revenue 31% a year on 65% gross margins.
Options expect by Oct 6±8.5%
Options expect by Oct 29±17.5%
Priced in for Oct 28 earnings±17.2%
IV rank (30-day)23% · cheap
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full GH picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on GH
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Guardant Health, Inc.

Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.

GH stock facts

Ticker symbolGH
ExchangeNASDAQ Global Select
SectorHealthcare
IndustryMedical - Diagnostics & Research
Market cap$23.8B
CEOHelmy Eltoukhy
Employees2,498
HeadquartersPalo Alto, CA, US
IPO date2018-10-04
Websiteguardanthealth.com

What you can see for GH on Tickr

Live GH price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the GH report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Guardant Health, Inc.?

The ticker symbol for Guardant Health, Inc. is GH, listed on the NASDAQ Global Select.

What is GH?

Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360…

HomeExploreMarketLists
All pages